Shin Poong Pharm.Co.,Ltd. (019170.KS)
KRW 10370.0
(-5.04%)
KRW 10370.0
(-5.04%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 78.61 Billion KRW | 0.83% |
| 2022 | 77.97 Billion KRW | 0.76% |
| 2021 | 77.38 Billion KRW | 1.12% |
| 2020 | 76.52 Billion KRW | 0.45% |
| 2019 | 76.18 Billion KRW | 0.39% |
| 2018 | 75.88 Billion KRW | -5.29% |
| 2017 | 80.12 Billion KRW | -8.88% |
| 2016 | 87.92 Billion KRW | 1.43% |
| 2015 | 86.68 Billion KRW | -14.14% |
| 2014 | 100.96 Billion KRW | 5.71% |
| 2013 | 95.51 Billion KRW | 6.85% |
| 2012 | 89.38 Billion KRW | -13.33% |
| 2011 | 103.13 Billion KRW | -6.86% |
| 2010 | 110.72 Billion KRW | 5.31% |
| 2009 | 105.15 Billion KRW | 9.73% |
| 2008 | 95.82 Billion KRW | 19.94% |
| 2007 | 79.89 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 20.04 Billion KRW | 2.84% |
| 2024 Q1 | 19.48 Billion KRW | 2.03% |
| 2023 Q1 | 19.14 Billion KRW | -14.33% |
| 2023 Q2 | 21.9 Billion KRW | 14.37% |
| 2023 Q4 | 19.09 Billion KRW | -2.58% |
| 2023 Q3 | 19.6 Billion KRW | -10.48% |
| 2023 FY | 78.61 Billion KRW | 0.83% |
| 2022 Q2 | 19.15 Billion KRW | 11.09% |
| 2022 Q4 | 22.35 Billion KRW | 16.31% |
| 2022 FY | 77.97 Billion KRW | 0.76% |
| 2022 Q3 | 19.21 Billion KRW | 0.32% |
| 2022 Q1 | 17.24 Billion KRW | -12.22% |
| 2021 Q1 | 20.49 Billion KRW | 15.81% |
| 2021 Q2 | 17.42 Billion KRW | -14.97% |
| 2021 Q3 | 19.82 Billion KRW | 13.78% |
| 2021 Q4 | 19.64 Billion KRW | -0.9% |
| 2021 FY | 77.38 Billion KRW | 1.12% |
| 2020 Q4 | 17.69 Billion KRW | -9.31% |
| 2020 Q1 | 19.12 Billion KRW | 4.51% |
| 2020 FY | 76.52 Billion KRW | 0.45% |
| 2020 Q3 | 19.51 Billion KRW | -3.41% |
| 2020 Q2 | 20.19 Billion KRW | 5.63% |
| 2019 Q3 | 20.14 Billion KRW | 5.8% |
| 2019 Q2 | 19.04 Billion KRW | 1.82% |
| 2019 Q1 | 18.7 Billion KRW | -8.94% |
| 2019 Q4 | 18.29 Billion KRW | -9.17% |
| 2019 FY | 76.18 Billion KRW | 0.39% |
| 2018 Q4 | 20.53 Billion KRW | 9.99% |
| 2018 FY | 75.88 Billion KRW | -5.29% |
| 2018 Q3 | 18.67 Billion KRW | -5.48% |
| 2018 Q2 | 19.75 Billion KRW | 16.74% |
| 2018 Q1 | 16.92 Billion KRW | -13.4% |
| 2017 Q2 | 20.9 Billion KRW | 5.12% |
| 2017 Q1 | 19.88 Billion KRW | 1.62% |
| 2017 FY | 80.12 Billion KRW | -8.88% |
| 2017 Q4 | 19.54 Billion KRW | -1.26% |
| 2017 Q3 | 19.79 Billion KRW | -5.32% |
| 2016 Q3 | 26.15 Billion KRW | 25.65% |
| 2016 Q4 | 19.56 Billion KRW | -25.18% |
| 2016 Q1 | 21.38 Billion KRW | -3.59% |
| 2016 FY | 87.92 Billion KRW | 1.43% |
| 2016 Q2 | 20.81 Billion KRW | -2.67% |
| 2015 FY | 86.68 Billion KRW | -14.14% |
| 2015 Q1 | 22.32 Billion KRW | -15.36% |
| 2015 Q4 | 22.18 Billion KRW | 12.34% |
| 2015 Q3 | 19.74 Billion KRW | -11.96% |
| 2015 Q2 | 22.42 Billion KRW | 0.48% |
| 2014 Q4 | 26.37 Billion KRW | -2.38% |
| 2014 Q1 | 22.67 Billion KRW | -4.36% |
| 2014 FY | 100.96 Billion KRW | 5.71% |
| 2014 Q2 | 24.89 Billion KRW | 9.75% |
| 2014 Q3 | 27.01 Billion KRW | 8.55% |
| 2013 Q2 | 28.24 Billion KRW | 14.26% |
| 2013 Q3 | 18.84 Billion KRW | -33.27% |
| 2013 Q4 | 23.71 Billion KRW | 25.82% |
| 2013 FY | 95.51 Billion KRW | 6.85% |
| 2013 Q1 | 24.71 Billion KRW | 7.72% |
| 2012 Q4 | 22.94 Billion KRW | -6.82% |
| 2012 FY | 89.38 Billion KRW | -13.33% |
| 2012 Q1 | 20.64 Billion KRW | 0.0% |
| 2012 Q2 | 19.92 Billion KRW | -3.53% |
| 2012 Q3 | 24.62 Billion KRW | 23.61% |
| 2011 Q2 | 25.1 Billion KRW | -9.84% |
| 2011 Q3 | 22.82 Billion KRW | -9.11% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 103.13 Billion KRW | -6.86% |
| 2011 Q1 | 27.84 Billion KRW | 0.0% |
| 2010 Q1 | 25.35 Billion KRW | 0.0% |
| 2010 FY | 110.72 Billion KRW | 5.31% |
| 2010 Q3 | 21.54 Billion KRW | -19.27% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 26.68 Billion KRW | 5.24% |
| 2009 Q1 | 23.67 Billion KRW | 0.0% |
| 2009 Q2 | 25.17 Billion KRW | 6.33% |
| 2009 Q3 | 26.58 Billion KRW | 5.61% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 105.15 Billion KRW | 9.73% |
| 2008 Q3 | 23.65 Billion KRW | -2.94% |
| 2008 Q1 | 21.44 Billion KRW | 0.0% |
| 2008 FY | 95.82 Billion KRW | 19.94% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 24.36 Billion KRW | 13.65% |
| 2007 Q3 | 18.59 Billion KRW | -16.37% |
| 2007 Q2 | 22.23 Billion KRW | 28.14% |
| 2007 Q1 | 17.35 Billion KRW | 0.0% |
| 2007 FY | 79.89 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -69.056% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 78.408% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 60.47% |
| HANDOK Inc. | 151.36 Billion KRW | 48.06% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -16.951% |
| Yuhan Corporation | 564.5 Billion KRW | 86.073% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 75.6% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -231.071% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 90.594% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -4.771% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 60.485% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -93.408% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 16.818% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 44.184% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -69.056% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -126.467% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -2.345% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 752.684% |
| JW Holdings Corporation | 446.15 Billion KRW | 82.378% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 62.118% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 88.003% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 76.578% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -4.495% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -8.874% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 57.229% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -69.056% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 73.36% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 88.465% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 76.578% |
| Yuhan Corporation | 564.5 Billion KRW | 86.073% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 61.045% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -10.827% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 20.608% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 76.578% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 46.111% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 54.683% |
| CKD Bio Corp. | 5.01 Billion KRW | -1469.162% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 69.076% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 57.301% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 19.878% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 0.0% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 78.837% |
| Boryung Corporation | 333.26 Billion KRW | 76.41% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -57.096% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 60.485% |
| JW Lifescience Corporation | 51.32 Billion KRW | -53.18% |